Detection of Biodefense Pathogens Using Phage Diagnostics

Information

  • Research Project
  • 9010924
  • ApplicationId
    9010924
  • Core Project Number
    R01AI111535
  • Full Project Number
    5R01AI111535-03
  • Serial Number
    111535
  • FOA Number
    RFA-AI-13-013
  • Sub Project Id
  • Project Start Date
    3/7/2014 - 10 years ago
  • Project End Date
    2/28/2018 - 6 years ago
  • Program Officer Name
    RITCHIE, ALEC
  • Budget Start Date
    3/1/2016 - 8 years ago
  • Budget End Date
    2/28/2018 - 6 years ago
  • Fiscal Year
    2016
  • Support Year
    03
  • Suffix
  • Award Notice Date
    3/2/2016 - 8 years ago
Organizations

Detection of Biodefense Pathogens Using Phage Diagnostics

DESCRIPTION (provided by applicant): Yersinia pestis and Bacillus anthracis are designated by the Centers for Disease Control and Prevention (CDC) as Category A bacterial pathogens and are the etiological agents for the plague and anthrax, respectively. Although the natural occurrence of each disease is rare, the possibility of terrorist groups using these pathogens as bioweapons is real. Because both conditions share common features such as rapid clinical course, and high mortality, it is critical that outbreaks be detected quickly. Therefore, methodologies that provide rapid detection and diagnosis are essential to ensure immediate implementation of public health measures and activation of crisis management. The goal of this research is to develop a diagnostic platform for the plague and anthrax. The CDC currently uses classical phage lysis assays as a standard for the confirmed identification of Y. pestis and B. anthracis. Although these assays are robust, they are laboratory based and require 24-48 h to complete. In order to overcome these limitations, we have generated recombinant light-tagged-reporter phages which can rapidly (within minutes), sensitively and specifically transduce a bioluminescent phenotype to Y. pestis and B. anthracis. We have demonstrated that the reporter phages can detect the target pathogens at clinically relevant concentrations during the early course of disease, and also generate antibiotic susceptibility profiles 5 to 10 times faster than conventional methods. This is key as the diseases are treatable as long as they are rapidly diagnosed, and appropriate therapy is initiated. We will continue with this research and transition the diagnostic technology to preclinical development with the goal of gaining FDA-approval. In the NIAID: Strategic Planning for the 21st Century, NIAID highlights the following priorities in the development of diagnostic assays: (i) specific to the pathogen; (ii cost effective; (iii) sensitive; (iv) multiplexed and high throughput, and (v) easy to use. This proposal is significant because the reporter phage technology can address these requirements, and has the potential to save lives by significantly improving our nation's defense against biological warfare.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R01
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
    202661
  • Indirect Cost Amount
    132376
  • Total Cost
    335037
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:335037\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZAI1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    GUILD ASSOCIATES, INC.
  • Organization Department
  • Organization DUNS
    001004258
  • Organization City
    DUBLIN
  • Organization State
    OH
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    430161234
  • Organization District
    UNITED STATES